Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial

Gastrointestinal Cancer

Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes

Eur J Cancer

Graus MUJE, van Diepen AE, Broekman T, van Eijck CWF, van Hooft JE, Homs MYV, Wumkes ML, Wilmink JW, de Hingh IHJT, Valkenburg-van Iersel LBJ, van der Geest LGM, Vos-Geelen J, Dutch Pancreatic Cancer Group (DPCG)

doi: 10.1016/j.ejca.2026.116263

Further Publications

Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival: A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial

JAMA Oncol

Richardson DR, Wang Y, Flannery M, Mohamed M, Magnuson A, Wells M, Tylock R, Soto-Perez-de-Celis E, DuMontier C, Dale W, Epstein R, Berenberg J, Ramdin N, Mohile S, Loh KP

doi: 10.1001/jamaoncol.2026.0072

Genitourinary Cancer

Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial

BJU Int

Sushentsev N, Warren AY, Colling R, Verrill C, Pazukhina E, Blyuss O, Zaikin A, Seibert TM, Barrett T, Oxley J, Mills IG, Bryant RJ, Lane JA, Donovan JL, Neal DE, Hamdy FC

doi: 10.1111/bju.70261

Gastrointestinal Cancer

Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial

Eur J Cancer

Cristarella E, Ambrosini M, Di Maio M, Lonardi S, De Vita F, Di Donato S, Giommoni E, Spallanzani A, Bittoni A, Chini C, Strippoli A, Latiano TP, Brunetti O, Tamberi S, Cardellino GG, Spada D, Fornaro L, Alessandrini S, Pietrantonio F, Randon G

doi: 10.1016/j.ejca.2025.116060

Genitourinary Cancer

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Ann Oncol

Tripathi A, Chen Y, Jarrard DF, Garcia JA, Dreicer R, Liu G, Hussain MH, Shevrin DH, Cooney MM, Eisenberger MA, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Carducci MA, DiPaola RS, Sweeney CJ

doi: 10.1016/j.annonc.2025.08.004

Genitourinary Cancer

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease

Eur Urol

Bellmunt J, Powles T, Park SH, Voog E, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Sternberg CN, Aragon-Ching JB, Petrylak DP, Climent Duran MA, Tyroller K, Hoffman J, Jacob N, Grivas P, Gupta S

doi: 10.1016/j.eururo.2025.05.017

Genitourinary Cancer

Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial

JAMA Oncol

Sushentsev N, Warren AY, Colling R, Verrill C, Pazukhina E, Blyuss O, Seibert TM, Barrett T, Mills IG, Bryant RJ, Donovan JL, Neal DE, Hamdy FC

doi: 10.1001/jamaoncol.2025.4125

Genitourinary Cancer

Impact of Intraprostatic Simultaneous Integrated Boost on Long-Term Outcomes in Unfavorable Intermediate-Risk Prostate Cancer Treated With Dose-Escalated Radiotherapy and Short-Term Androgen Deprivation Therapy

Prostate

Onal C, Elmali A, Demirhan B, Senturk E, Erpolat P, Guler OC

doi: 10.1002/pros.70167

Lung, Respiratory and Thoracic Cancer

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Lancet Oncol

Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B

doi: 10.1016/S1470-2045(25)00429-2

Related content

Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes

Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival: A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial

Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial

Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease

Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial

Impact of Intraprostatic Simultaneous Integrated Boost on Long-Term Outcomes in Unfavorable Intermediate-Risk Prostate Cancer Treated With Dose-Escalated Radiotherapy and Short-Term Androgen Deprivation Therapy

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis